[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:chondrosarcoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":86,"states":87},"Chondrosarcoma",12,9,[8,16,23,29,35,42,48,54,60,66,73,80],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06127407","Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen",[12],"Phase 3","RECRUITING","2026-08-26T02:16:47.762107Z","2026-05-05T02:43:27.752538Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07193550","A Phase 2 Trial of Zanzalintinib in Advanced\u002FMetastatic Bone Sarcomas (ZAMBONE)",[20],"Phase 2","2026-08-26T02:16:35.654046Z","2026-05-05T02:43:28.850363Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04040205","Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration",[20],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:28.417090Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06176989","Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors",[20],"2026-08-26T02:17:21.315591Z","2026-06-16T05:54:07.915642Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT05039801","IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors",[39],"Phase 1","2026-08-26T02:18:49.989941Z","2026-04-29T02:57:57.070174Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06387485","A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning",[],"2026-08-26T02:18:34.622081Z","2026-05-05T02:43:28.883449Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT03442465","Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas",[],"2026-08-26T02:16:24.135291Z","2026-05-13T02:55:06.124870Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06749366","Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing",[],"2026-08-26T02:15:42.447052Z","2026-05-13T02:55:06.568565Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05033288","Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone",[],"2026-08-26T02:17:15.156099Z","2026-05-13T02:55:06.280317Z",{"nct_id":67,"title":68,"phases":69,"status":70,"updated_at":71,"content_modified":72},"NCT06029478","Understanding Engagement Trends in Chondrosarcoma Clinical Trials",[],"NOT_YET_RECRUITING","2026-08-26T02:18:38.865010Z","2026-05-13T02:55:06.401678Z",{"nct_id":74,"title":75,"phases":76,"status":77,"updated_at":78,"content_modified":79},"NCT04673942","A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:35:59.254098Z","2026-05-05T02:43:26.752039Z",{"nct_id":81,"title":82,"phases":83,"status":77,"updated_at":84,"content_modified":85},"NCT04087902","Long-Term Longitudinal QoL in Patients Undergoing EEA",[],"2026-08-03T03:02:05.931134Z","2026-05-13T02:55:06.184138Z",[],[88,92,95,98,102],{"state":89,"count":90,"slug":91},"California",4,"california",{"state":93,"count":90,"slug":94},"Ohio","ohio",{"state":96,"count":90,"slug":97},"Texas","texas",{"state":99,"count":100,"slug":101},"Florida",3,"florida",{"state":103,"count":100,"slug":104},"Maryland","maryland"]